These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 10523797)

  • 21. A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy.
    Wongprajun S; Auewarakul CU
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S157-64. PubMed ID: 20364570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia.
    Knechtli CJ; Goulden NJ; Hancock JP; Grandage VL; Harris EL; Garland RJ; Jones CG; Rowbottom AW; Hunt LP; Green AF; Clarke E; Lankester AW; Cornish JM; Pamphilon DH; Steward CG; Oakhill A
    Blood; 1998 Dec; 92(11):4072-9. PubMed ID: 9834212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of minimal residual disease in a patient having acute myelogenous leukemia with t(16;21)(p11;q22) treated by allogeneic bone marrow transplantation.
    Okoshi Y; Shimizu S; Kojima H; Obara N; Mukai HY; Komeno T; Hasegawa Y; Mori N; Nagasawa T
    Acta Haematol; 2001; 105(1):45-8. PubMed ID: 11340253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients.
    Björklund E; Gruber A; Mazur J; Mårtensson A; Hansson M; Porwit A
    Int J Hematol; 2009 Oct; 90(3):292-302. PubMed ID: 19728029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
    Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
    Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.
    Pemmaraju N; Kantarjian H; Jorgensen JL; Jabbour E; Jain N; Thomas D; O'Brien S; Wang X; Huang X; Wang SA; Konopleva M; Konoplev S; Kadia T; Garris R; Pierce S; Garcia-Manero G; Cortes J; Ravandi F
    Am J Hematol; 2017 Mar; 92(3):279-285. PubMed ID: 28052371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
    Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
    Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A
    Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Application of triple-color flow cytometry for minimal residual disease detection in acute B-lymphoblastic leukemia].
    Chen T; Zhu Y; Zhou X; Wang Y; Ying D
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jan; 22(1):20-3. PubMed ID: 11877045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of minimal residual disease in acute leukemia by flow cytometry.
    Campana D; Coustan-Smith E
    Cytometry; 1999 Aug; 38(4):139-52. PubMed ID: 10440852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
    Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
    Bone Marrow Transplant; 2000 Apr; 25(8):843-51. PubMed ID: 10808205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal residual disease status in pre-B acute lymphoblastic leukemia patients after chemotherapy and bone marrow transplantation: assessment of the anti-leukemic effects of chemotherapy and BMT.
    Kiyoi H; Naoe T; Yamauchi T; Fukatani H; Kubo K; Kojima S; Ohno R
    Leuk Res; 1993 Aug; 17(8):677-84. PubMed ID: 8355512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
    Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of multiparametric flow cytometry in the detection of minimal residual disease in acute leukaemia.
    Lee D; Grigoriadis G; Westerman D
    Pathology; 2015 Dec; 47(7):609-21. PubMed ID: 26517623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Status of minimal residual disease testing in childhood haematological malignancies.
    Campana D
    Br J Haematol; 2008 Nov; 143(4):481-9. PubMed ID: 18710378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
    Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse.
    Miglino M; Berisso G; Grasso R; Canepa L; Clavio M; Pierri I; Pietrasanta D; Gatto S; Varaldo R; Ballerini F; Verdiani S; Casarino L; DeStefano F; Sessarego M; Dominietto A; Raiola AM; Bregante S; di Grazia C; Gobbi M; Bacigalupo A
    Bone Marrow Transplant; 2002 Nov; 30(9):579-85. PubMed ID: 12407432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia.
    Knechtli CJ; Goulden NJ; Hancock JP; Harris EL; Garland RJ; Jones CG; Grandage VL; Rowbottom AW; Green AF; Clarke E; Lankester AW; Potter MN; Cornish JM; Pamphilon DH; Steward CG; Oakhill A
    Br J Haematol; 1998 Aug; 102(3):860-71. PubMed ID: 9722317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.